Effect of anti-coagulant choice on cord blood processing results

Michael Badowski, Chris Shultz, David T. Harris

Research output: Contribution to journalArticle

Abstract

Background aims: Cord blood (CB) is a valuable source of stem cells for hematopoietic stem cell transplantation and regenerative medicine applications. CB collection commonly uses either lyophilized heparin (LH; 500 units) or liquid citrate phosphate dextrose (CPD; 35 mL) as an anti-coagulant, but it is unclear if the choice of anti-coagulant can affect CB quality. Methods: CB was collected in either LH or CPD bags with a simulated transit period of 24 h, followed by processing (with the use of the automated, high-throughput AutoXpress Platform [AXP]). CB characteristics were assessed at collection (time 0 h) and then again after processing at time 24 h. Results: After AXP processing, samples collected and held in LH had significantly greater viable total nucleated cells (TNC) TNC and mononuclear cells (MNC) MNC. CD34 recoveries were not statistically different at 24 h, but there was a trend for samples collected and held in CPD to contain more colony-forming units. Conclusions: CB processing using the AXP methodology appears to be equivalent with either LH or CPD anti-coagulants.

Original languageEnglish (US)
JournalCytotherapy
DOIs
StateAccepted/In press - 2014

Fingerprint

Coagulants
Fetal Blood
Stem Cells
Regenerative Medicine
Hematopoietic Stem Cell Transplantation
Heparin

Keywords

  • anti-coagulant
  • CD34
  • CFU
  • cord blood
  • processing

ASJC Scopus subject areas

  • Transplantation
  • Oncology
  • Immunology and Allergy
  • Genetics(clinical)
  • Immunology
  • Cell Biology
  • Cancer Research

Cite this

Effect of anti-coagulant choice on cord blood processing results. / Badowski, Michael; Shultz, Chris; Harris, David T.

In: Cytotherapy, 2014.

Research output: Contribution to journalArticle

@article{f23805c1d0df499aae67a89764931921,
title = "Effect of anti-coagulant choice on cord blood processing results",
abstract = "Background aims: Cord blood (CB) is a valuable source of stem cells for hematopoietic stem cell transplantation and regenerative medicine applications. CB collection commonly uses either lyophilized heparin (LH; 500 units) or liquid citrate phosphate dextrose (CPD; 35 mL) as an anti-coagulant, but it is unclear if the choice of anti-coagulant can affect CB quality. Methods: CB was collected in either LH or CPD bags with a simulated transit period of 24 h, followed by processing (with the use of the automated, high-throughput AutoXpress Platform [AXP]). CB characteristics were assessed at collection (time 0 h) and then again after processing at time 24 h. Results: After AXP processing, samples collected and held in LH had significantly greater viable total nucleated cells (TNC) TNC and mononuclear cells (MNC) MNC. CD34 recoveries were not statistically different at 24 h, but there was a trend for samples collected and held in CPD to contain more colony-forming units. Conclusions: CB processing using the AXP methodology appears to be equivalent with either LH or CPD anti-coagulants.",
keywords = "anti-coagulant, CD34, CFU, cord blood, processing",
author = "Michael Badowski and Chris Shultz and Harris, {David T.}",
year = "2014",
doi = "10.1016/j.jcyt.2014.05.002",
language = "English (US)",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Effect of anti-coagulant choice on cord blood processing results

AU - Badowski, Michael

AU - Shultz, Chris

AU - Harris, David T.

PY - 2014

Y1 - 2014

N2 - Background aims: Cord blood (CB) is a valuable source of stem cells for hematopoietic stem cell transplantation and regenerative medicine applications. CB collection commonly uses either lyophilized heparin (LH; 500 units) or liquid citrate phosphate dextrose (CPD; 35 mL) as an anti-coagulant, but it is unclear if the choice of anti-coagulant can affect CB quality. Methods: CB was collected in either LH or CPD bags with a simulated transit period of 24 h, followed by processing (with the use of the automated, high-throughput AutoXpress Platform [AXP]). CB characteristics were assessed at collection (time 0 h) and then again after processing at time 24 h. Results: After AXP processing, samples collected and held in LH had significantly greater viable total nucleated cells (TNC) TNC and mononuclear cells (MNC) MNC. CD34 recoveries were not statistically different at 24 h, but there was a trend for samples collected and held in CPD to contain more colony-forming units. Conclusions: CB processing using the AXP methodology appears to be equivalent with either LH or CPD anti-coagulants.

AB - Background aims: Cord blood (CB) is a valuable source of stem cells for hematopoietic stem cell transplantation and regenerative medicine applications. CB collection commonly uses either lyophilized heparin (LH; 500 units) or liquid citrate phosphate dextrose (CPD; 35 mL) as an anti-coagulant, but it is unclear if the choice of anti-coagulant can affect CB quality. Methods: CB was collected in either LH or CPD bags with a simulated transit period of 24 h, followed by processing (with the use of the automated, high-throughput AutoXpress Platform [AXP]). CB characteristics were assessed at collection (time 0 h) and then again after processing at time 24 h. Results: After AXP processing, samples collected and held in LH had significantly greater viable total nucleated cells (TNC) TNC and mononuclear cells (MNC) MNC. CD34 recoveries were not statistically different at 24 h, but there was a trend for samples collected and held in CPD to contain more colony-forming units. Conclusions: CB processing using the AXP methodology appears to be equivalent with either LH or CPD anti-coagulants.

KW - anti-coagulant

KW - CD34

KW - CFU

KW - cord blood

KW - processing

UR - http://www.scopus.com/inward/record.url?scp=84901893430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901893430&partnerID=8YFLogxK

U2 - 10.1016/j.jcyt.2014.05.002

DO - 10.1016/j.jcyt.2014.05.002

M3 - Article

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

ER -